Atrial Fibrillation
Conditions
Keywords
Non-valvular atrial fibrillation (NVAF), Prevention, Stroke
Brief summary
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
Interventions
As prescribed by treating physicians
As prescribed by treating physicians
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non-valvular atrial fibrillation will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD-9 427.31 (International Classification of Disease, Ninth Revision, Clinical Modification) as the diagnosis code at any time in the patient's data history prior to inclusion * Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics * CHA2DS2-Vasc (Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category ) score ≥2 during the 180 days prior to index dabigatran use baseline period
Exclusion criteria
* Patients \<18 years of age * Patients with valvular Atrial fibrillation * Pregnancy * Malignant cancers * Transient cause of Atrial fibrillation * Patients with Venous thromboembolism (pulmonary embolism or Deep Vein Thrombosis) * Patients with major surgery defined as hip or knee replacement * Prescriptions of Oral anticoagulants (OACs) {apixaban, warfarin, dabigatran, rivaroxaban} before index date * Prescription of more than one OAC on the index date * Patient with any of the events defined in the composite endpoint
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Hospitalization Events (composite endpoint) | Within 2 years of starting treatment |
Countries
United States
Outcome results
None listed